LVM Capital Management Ltd. MI Sells 554 Shares of Stryker Co. (NYSE:SYK)

LVM Capital Management Ltd. MI lessened its position in shares of Stryker Co. (NYSE:SYK) by 1.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,260 shares of the medical technology company’s stock after selling 554 shares during the period. Stryker makes up about 1.4% of LVM Capital Management Ltd. MI’s portfolio, making the stock its 19th largest holding. LVM Capital Management Ltd. MI’s holdings in Stryker were worth $13,416,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Parnassus Investments LLC bought a new position in shares of Stryker in the 3rd quarter valued at $762,798,000. Baltimore Washington Financial Advisors Inc. raised its stake in Stryker by 2.4% during the third quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company’s stock worth $24,089,000 after acquiring an additional 1,554 shares in the last quarter. Sivik Global Healthcare LLC raised its stake in Stryker by 8.0% during the third quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock worth $9,754,000 after acquiring an additional 2,000 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Stryker by 2.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company’s stock valued at $210,289,000 after purchasing an additional 16,504 shares in the last quarter. Finally, World Investment Advisors LLC grew its holdings in shares of Stryker by 126.1% during the 3rd quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company’s stock valued at $2,941,000 after purchasing an additional 4,541 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is currently owned by company insiders.

Stryker Stock Up 0.6 %

SYK stock traded up $2.32 during mid-day trading on Friday, reaching $366.42. 607,542 shares of the company traded hands, compared to its average volume of 1,157,611. The firm’s 50 day moving average price is $375.42 and its 200 day moving average price is $357.51. Stryker Co. has a fifty-two week low of $306.10 and a fifty-two week high of $398.20. The stock has a market cap of $139.69 billion, a price-to-earnings ratio of 39.27, a P/E/G ratio of 2.82 and a beta of 0.95. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same quarter in the prior year, the business posted $2.46 EPS. The business’s revenue was up 11.9% compared to the same quarter last year. As a group, equities research analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker’s dividend payout ratio is currently 36.01%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of research reports. Barclays boosted their target price on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. BTIG Research increased their target price on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a report on Tuesday. Piper Sandler reissued an “overweight” rating and issued a $420.00 price objective (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Finally, UBS Group lifted their target price on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.